Evidence map›Paper›PMID 36961404›Full record

ArticleCancer immunology research2023

The Immunopeptidome from a Genomic Perspective: Establishing the Noncanonical Landscape of MHC Class I-Associated Peptides.

Georges Bedran, Hans-Christof Gasser, Kenneth Weke, Tongjie Wang, Dominika Bedran, Alexander Laird, Christophe Battail, Fabio Massimo Zanzotto, Catia Pesquita, Håkan Axelson and 14 more

Abstract read
In one paragraph

Article in Cancer immunology research, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
  4. Review
  5. Review
  6. Review
  7. Unlocking cancer vaccine potential: What are the key factors?Human vaccines & immunotherapeutics · 2024
    Review
  8. Article
  9. Article
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

24 authors.

Georges BedranInternational Centre for Cancer Vaccine Science, University of Gdansk, Gdansk, Poland.ORCID 0000-0002-3086-3742
Hans-Christof GasserSchool of Informatics, University of Edinburgh, Edinburgh, United Kingdom.ORCID 0000-0003-1274-4966
Kenneth WekeInternational Centre for Cancer Vaccine Science, University of Gdansk, Gdansk, Poland.ORCID 0000-0001-8947-7793
Tongjie WangSchool of Informatics, University of Edinburgh, Edinburgh, United Kingdom.ORCID 0000-0001-9237-156X
Dominika BedranInternational Centre for Cancer Vaccine Science, University of Gdansk, Gdansk, Poland.ORCID 0000-0002-2263-2493
Alexander LairdUrology Department, Western General Hospital, NHS Lothian, Edinburgh, United Kingdom.ORCID 0000-0002-7296-025X
Christophe BattailCEA, Grenoble Alpes University, INSERM, IRIG, Biosciences and Bioengineering for Health Laboratory (BGE) - UA13 INSERM-CEA-UGA, Grenoble, France.ORCID 0000-0001-6849-7824
Fabio Massimo ZanzottoDepartment of Enterprise Engineering, University of Rome "Tor Vergata", Rome, Italy.ORCID 0000-0002-7301-3596
Catia PesquitaLASIGE, Faculdade de Ciências, Universidade de Lisboa, Lisboa, Portugal.ORCID 0000-0002-1847-9393
Håkan AxelsonDivision of Translational Cancer Research, Department of Laboratory Medicine, Lund University, Lund, Sweden.ORCID 0000-0002-7749-5043
Ajitha RajanSchool of Informatics, University of Edinburgh, Edinburgh, United Kingdom.ORCID 0000-0003-3765-3075
David J HarrisonSchool of Medicine, University of St Andrews, St Andrews, United Kingdom.ORCID 0000-0001-9041-9988
Aleksander PalkowskiInternational Centre for Cancer Vaccine Science, University of Gdansk, Gdansk, Poland.ORCID 0000-0002-3140-8469
Maciej PawlikAcademic Computer Centre CYFRONET, AGH University of Science and Technology, Cracow, Poland.ORCID 0000-0003-3419-7262
Maciej ParysRoyal (Dick) School of Veterinary Studies and The Roslin Institute, University of Edinburgh, Edinburgh, United Kingdom.ORCID 0000-0003-4456-3369
J Robert O'NeillCambridge Oesophagogastric Centre, Cambridge University Hospitals NHS Foundation Trust, Cambridge, United Kingdom.ORCID 0000-0003-2230-7137
Paul M BrennanTranslational Neurosurgery, Centre for Clinical Brain Sciences, University of Edinburgh, Edinburgh, United Kingdom.ORCID 0000-0002-7347-830X
Stefan N SymeonidesInstitute of Genetics and Cancer, University of Edinburgh, Edinburgh, United Kingdom.ORCID 0000-0002-9892-9314
David R GoodlettInternational Centre for Cancer Vaccine Science, University of Gdansk, Gdansk, Poland.ORCID 0000-0002-8045-8200
Kevin LitchfieldCancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, London, United Kingdom.ORCID 0000-0002-3725-0914
Robin FahraeusInternational Centre for Cancer Vaccine Science, University of Gdansk, Gdansk, Poland.ORCID 0000-0003-0402-8492
Ted R HuppInternational Centre for Cancer Vaccine Science, University of Gdansk, Gdansk, Poland.ORCID 0000-0003-0391-0352
Sachin KoteInternational Centre for Cancer Vaccine Science, University of Gdansk, Gdansk, Poland.ORCID 0000-0002-2431-9935
Javier A AlfaroInternational Centre for Cancer Vaccine Science, University of Gdansk, Gdansk, Poland.ORCID 0000-0002-5553-6991

Funding

Medical Research Council MR/V033077/1
6 · The paper itself

Abstract

Tumor antigens can emerge through multiple mechanisms, including translation of noncoding genomic regions. This noncanonical category of tumor antigens has recently gained attention; however, our understanding of how they recur within and between cancer types is still in its infancy. Therefore, we developed a proteogenomic pipeline based on deep learning de novo mass spectrometry (MS) to enable the discovery of noncanonical MHC class I-associated peptides (ncMAP) from noncoding regions. Considering that the emergence of tumor antigens can also involve posttranslational modifications (PTM), we included an open search component in our pipeline. Leveraging the wealth of MS-based immunopeptidomics, we analyzed data from 26 MHC class I immunopeptidomic studies across 11 different cancer types. We validated the de novo identified ncMAPs, along with the most abundant PTMs, using spectral matching and controlled their FDR to 1%. The noncanonical presentation appeared to be 5 times enriched for the A03 HLA supertype, with a projected population coverage of 55%. The data reveal an atlas of 8,601 ncMAPs with varying levels of cancer selectivity and suggest 17 cancer-selective ncMAPs as attractive therapeutic targets according to a stringent cutoff. In summary, the combination of the open-source pipeline and the atlas of ncMAPs reported herein could facilitate the identification and screening of ncMAPs as targets for T-cell therapies or vaccine development.

Indexed as

Histocompatibility Antigens Class INeoplasmsAntigens, NeoplasmGenomicsHumansPeptidesAntigens, NeoplasmHistocompatibility Antigens Class IPeptides

Identifiers

PMID36961404
PMCPMC10236148

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.